top of page

IBIS Therapeutics

Accelerating drug discovery through Molecular Fingerprint™ Platform

The only AI-based firm providing integrated solutions for: 

Transformed road sign as symbol of coming together

Novel Drug Discovery

Selectivity and Safety Assessment

Phenotypic Target Deconvolution

Polypharmacology Prediction

Currently, the 22,000 off-targets and co-targets in the human genome - including all their mutations and variants - are addressed individually

1 disease one gene one target one drug

The Problem

A narrowed view leads to a lack of on-target efficacy and unwanted off-target toxicity

The Solution

01

Hit and Lead Finding

02

Lead Optimization

button
hand pressing button

03

Animal Trials

04

Human Trials

oncology immuno-onc anti target and inflamation target approved drrugs and novel drug discovery chart

Engagement

ibis platform button
group collaboration chart

Collaborative Research

  • Investigate use of Ibis safety profiling across multiple projects and therapeutic areas

  • Generate machine learning models for toxicity profiling using Ibis Molecular Fingerprint™ Platform

discovery services
hands shaking in blue and white

Partnered Discovery

Discovery Services

  • Prioritize compounds for synthesis based upon off-target safety profiles

  • Explore effects of various target mutations upon drug binding

  • Deconvolute targets from phenotypic assays

  • Ibis out-licenses dug-target-disease combinations for drug repurposing

  • Ibis out-licenses novel preclinical assets developed in-house 

bottom of page